The results of our studies on the extraction and disposition of three plasticizing substances which are extracted from poly(vinyl chloride) medical devices will be reported. The plasticizers are di-2-ethylhexyl phthalate (DEHP), di-2-ethylhexyl adipate (DEHA), and butylglycolyl butyl phthalate (BGBP). DEHP extraction will be described in greater detail, and the two other plasticizers, DEHA and BGBP, will only be mentioned briefly.
The results of our studies on the extraction and disposition of three plasticizing substances which are extracted from poly(vinyl chloride) medical devices will be reported. The plasticizers are di-2-ethylhexyl phthalate (DEHP), di-2-ethylhexyl adipate (DEHA), and butylglycolyl butyl phthalate (BGBP). DEHP extraction will be described in greater detail, and the two other plasticizers, DEHA and BGBP, will only be mentioned briefly.
The compound DEHP is an aromatic diacid ester that meets the physical criteria needed to soften and plasticize the rigid polymer poly(vinyl chloride) (PVC). As a plasticizer the material is added to PVC during manufacture and may represent between 20 and 40% of the finished weight of the plastic. The plasticizing agent is not firmly bound to the plastic but is in loose solution and, as such, may be extracted by a variety of organic solvents. Unfortunately, the plasticizer is to some extent soluble in biologic fluids such as blood and blood plasma. This is the key to this report. The present series of studies began with an unknown compound isolated from a liver perfusion system. This substance was characterized as a phthalate ester and was a metabolite of the plasticizer, BGBP. Subsequent investigation disclosed that yet another type of plastic tubing also resulted in contamination of the perfusate. The substance found in this case was not a metabolite, but the intact plasticizer. The results of an experiment with this type of tubing are shown in Figure 1 . The tubing of the liver perfusion system was assembled, and perfusate (a blood and albumin solution) was pumped through the tubing in the absence of a liver. An amount of the same perfusion fluid was kept in the chamber at 370C for the entire perfusion time. This was called noncirculated perfusion fluid. An organic extract of both perfusates was prepared, and analysis by thin-layer chromatography was performed. As can be seen, the sample of circulated perfusion fluid contains DEHP while the noncirculated perfusion fluid does not. 
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PVC plastic blood bags. Thus, contamination of human blood occurred during storage. It is also interesting to note that another plasticizer, DEHA, was not present in the blood that came from the blood bank, but after circulation within the tubing. DEHA concentrations reached 2.14 and 4.99 mg/100 ml.
We attempted to establish the rate of DEHP extraction from plastic blood bags. It is more likely that blood might be contaminated during 21 day storage in plastic blood bags than it would be on circulation through plastic tubing. Therefore, units of human blood were obtained from the Johns Hopkins blood bank after 7, 11, 14, and 21 days of storage. The blood samples were analyzed for DEHP content. Samples of blood were also taken from units of dog blood which had been drawn and stored in a manner similar to that employed for human blood. The results of this experiment (2) , shown in Figure 3 , indicate that the rate of DEHP accumulation in blood was 0.25 mg/100 ml/day over a period of 21 days of storage. It is also apparent that dog and human blood did not differ in their rates of extraction. We carried our studies further and attempted to evaluate the amount of DEHP found in a fraction of whole blood, human platelet concentrates (Table 2) . Five platelet concentrates were obtained from Johns Hop- days.
We felt that another question should be asked: what becomes of DEHP which might subsequently be administered to a human? In our initial experiments, an acacia emulsion of DEHP was prepared and injected into the rat peritoneal cavity; 24 hr after injection of the emulsion the rat was sacrificed, and a midline incision made. Figure 5 shows the vicera of a rat after administration of the emulsion. The peritoneal cavity of this rat contained a great deal of ascitic fluid. Also, large white masses distributed throughout the peritoneal cavity were evident. Histologic examination indicated that the masses were serofibroid in nature, containing degenerating neutrophils and macrophages. The histopathology result suggested that the masses originated from a chemical peritonitis, possibly due to the administration of a material which was irritating to the peritoneal cavity. Control rats (given 3% acacia) were found to be unaffected by the vehicle.
To further clarify the fate of DEHP, emulsions were injected (IP) into rats which were then sacrificed at intervals after the injection. A whole-body homogenate was prepared, and aliquots sampled to determine the amount of DEHP which remained in the body after 2, 4, and 13 days. Figure 6 shows that the rate of DEHP disappearance after interperitoneal administration was quite slow. At 13 days, approximately 25% of the initial injected dose still remained. This fact, Days post injection FIGURE 6. DEHP disappearance after intraperitoneal administration.
coupled with the rather marked peritoneal irritation and inflammation observed, might suggest that di-2-ethylhexyl phthalate is metabolically inert and irritating. Because we found DEHP to be extracted by perfusion fluid in the isolated perfusedliver system we attempted to determine the fate of the DEHP in that system. We prepared perfusion fluid which contained 70-80 Mg/ml DEHP and measured the total concentration of the system at zero time and after 0.5 and 4.5 hr. At the end of the perfusion the liver was removed, homogenized, and assayed for total DEHP content. The result (Fig. 7) indicates that within 30 min of perfusion, 90% of the total DEHP contained in the perfusate phase of the system has disappeared while in the remaining 4 hr an additional 9% was lost. At the end of 4.5 hr, the perfusate was essentially cleared of DEHP, but almost all the DEHP was recovered from the liver. This result is in marked contrast to our observations with BGBP, where we found a significant amount of metabolite in the perfusate. In the DEHP perfusion at 4.5 hr, no trace of phthalic acid was found. Phthalic acid would be the expected de-esterified metabolite of DEHP. Because of the observation of accumulation by the isolated perfused liver system, we injected 40 mg of DEHP intravenously into two rats. The rats were sacrificed 24 hr later and tissue concentrations of DEHP determined. The results (Table 3) indicate that liver and lung contain the largest total amounts of the recovered dose. The carcass was also found to contain large amounts of DEHP but at a relatively low concentration. The spleen had a higher concentration, but only about 3% of the injected dose was found. The other tissues contained very little. The total amount of DEHP recovered was 79.1% of the injected dose. In similar experiments we were never able to find any trace of phthalic acid in the urine. This result might suggest that DEHP is inert in terms of the rat's ability to metabolize it to phthalic acid following IV injection. It is also possible that if DEHP is metabolized, it is converted to something other than phthalic acid per se.
If DEHP is extracted by blood from tubing and containers in which it is transported and stored, the possibility exists that this foreign compound may be administered to the human either when blood is admin- Because our results indicated that some but not all patients had measurable amounts of DEHP in their body tissues, we attempted to follow one person who was to undergo open heart surgery. This patient would presumably receive DEHP from transfusions or from exposure to PVC tubing. Samples of urine were obtained from the patient for 2 days before surgery and for 5 days following surgery. The urine was acidified, extracted with ether, and analyzed directly for phthalic acid. It was also treated by the method of Shaffer et al. (3), i.e., the urine was hydrolyzed with acid and base in an attempt to determine whether some other form of phthalic acid was present. The results (Fig. 8) indicate that this was indeed the case. Prior to surgery, phthalic acid was present in the urine of this patient. However, in the period immediately following surgery, a total phthalate equivalent of 43 mg DEHP was calculated. We calculated that 23 mg resulted from known transfusions. The remaining 20 mg DEHP was probably received during the 1.5 hr bypass interval. It is apparent that not only is DEHP extracted from -tubing by blood and transfused into human beings, but it does appear to be metabolized by the human. It is, however, metabolized to a form other than phthalic acid. This latter point was studied further with three normal subjects; myself and two other graduate students, who donated urine samples for this study (Table 5 ). The urine, treated by the method of Shaffer et al., was found to contain amounts of phthalic acid, as did the urine from patient RM 2 days prior to surgery. This result would suggest that there are some phthalate compounds to which humans are exposed through environmental routes, possibly airborne inhalation of particles of plasticizers, its vapors, or by direct ingestion of phthalates from food.
In conclusion, these studies have shown that several plasticizers may be extracted from PVC tubing by human do not contain any additive and as such, will not contribute any material to blood or its fractions that are stored or transported in them.
